Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rigosertib · ON-01910

Small molecule · Antagonist of Ras-binding domain of Ras effector proteins, Raf kinase and phosphatidylinositol 3-kinase (PI3K) · developed by Traws Pharma

Phase 3 Most advanced trial (none active)
TRAW Developer
6 Registered trials

What is Rigosertib?

Rigosertib (ON 01910.Na) is a synthetic benzyl styryl sulfone analogue that acts as a Ras mimetic. It binds the Ras-binding domain of Ras effector proteins such as Raf kinase and PI3K, preventing Ras from engaging its targets and inhibiting downstream signaling, cell cycle progression and proliferation. It has been studied in advanced solid tumors, hepatoma, and myelodysplastic syndromes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ON-01910, ON 01910.Na, SyB L-1101
Drug type
Small molecule
Targets
Ras-binding domain of Ras effector proteins, Raf kinase, phosphatidylinositol 3-kinase (PI3K)
Mechanism
Antagonist of Ras-binding domain of Ras effector proteins, Raf kinase and phosphatidylinositol 3-kinase (PI3K)
Pathways
Ras/Raf/Erk signaling, Ras/CRAF/Plk1 signaling, Ras/PI3K/Akt signaling, cell cycle arrest, apoptosis
Therapy area
Hematology, Oncology
Developer
Traws Pharma, Inc. (TRAW)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
67DOW7F9GL

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02562443 Phase 3 Myelodysplastic Syndrome Terminated TRAW
NCT01928537 Phase 3 Myelodysplastic Syndromes Completed TRAW
NCT01241500 Phase 3 Myelodysplastic Syndromes Completed TRAW
NCT01904682 Phase 2 Myelodysplastic Syndromes Completed TRAW
NCT00861783 Phase 1 Hepatoma Completed TRAW
NCT00861328 Phase 1 Advanced Solid Tumors Completed TRAW

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorChronic Myelomonocytic LeukemiaCytopeniaHepatomaMDSMyelodysplastic SyndromeRAEBRefractory Anemia With Excess Blasts

More from Traws Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.

Follow TRAW, the company behind Rigosertib

See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TRAW catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.